Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. (SION): 8 pipeline candidates · 3 upcoming catalysts · ~15 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
15.3 months
D/E 0.06 · 0% dilution
Lead: Phase 2
8 candidates
3 upcoming, next in ~12d
0 buys · 26 sells (180d)
A transparent, data-derived signal for Sionna Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.6B
Cash
$64.3M
Quarterly Burn
$21.8M
Runway
15.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| galicaftor | Phase 2 |
| navocaftor | Phase 2 |
| sion-109 | Phase 1 |
| sion-2222 | Phase 1 |
| sion-2851 | Phase 2 |
| sion-3067 | Phase 2 |
| sion-451 | Phase 1 |
| sion-719 | Phase 2 |
Upcoming Catalysts (3)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$1.43B
| Holder | Shares | Value |
|---|---|---|
| ra capital management, l.p. | 9,905,045 | $397.1M |
| orbimed advisors llc | 3,530,702 | $141.5M |
| viking global investors lp | 3,195,181 | $128.1M |
| enavate sciences gp, llc | 2,478,030 | $99.3M |
| vanguard capital management llc | 2,058,994 | $82.5M |
| jennison associates llc | 1,451,220 | $58.2M |
| perceptive advisors llc | 1,316,878 | $52.8M |
| blackrock, inc. | 1,295,867 | $52.0M |
| citadel advisors llc | 1,166,931 | $46.8M |
| deerfield management company, l.p. | 970,590 | $38.9M |
Showing top 10 of 119 institutional holders of Sionna Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Sionna Therapeutics, Inc.'s pipeline?
Sionna Therapeutics, Inc. (SION) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Sionna Therapeutics, Inc.'s lead drug candidate?
Sionna Therapeutics, Inc.'s most advanced tracked candidate is galicaftor (Phase 2) for Cystic fibrosis.
What is Sionna Therapeutics, Inc.'s next catalyst?
Sionna Therapeutics, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: sion-719" — expected June 30, 2026.
What is Sionna Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Sionna Therapeutics, Inc. has approximately 15.3 months of cash runway.
What is Sionna Therapeutics, Inc.'s market capitalization?
Sionna Therapeutics, Inc.'s market capitalization is approximately $1.6B.
Get the full picture on Sionna Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.